Glenmark Pharmaceuticals Limited ta sami izini daga mai kula da magungunan Indiya, Drug Controller General of India (DCGI), don gudanar da gwajin asibiti na Phase 1 na ƙaramin ƙwayar ƙwayar ƙwayar cuta, GRC 54276, mai hana hematopoietic progenitor kinase 1 (HPK1). GRC 54276 yana ɗaya daga cikin litattafan litattafai da yawa daga mazaunin Glenmark, Ƙungiyoyin Magungunan Innovative, wanda Dokta Nikhil Amin ke jagoranta, Babban Jami'in Kimiyya, wanda ya ƙware a ci gaban sabbin ƙwayoyin ƙwayoyin cuta don mahimman buƙatun likita waɗanda ba su cika ba. HPK1 shine maɓalli mai mahimmanci na ƙwayoyin T, B cell da dendritic cell-matsakaicin martani na rigakafi, wanda ke inganta rigakafi na antitumor ta kunnawa da ƙaddamar da ƙwayoyin T. GRC 54276 ya nuna ikon kashe ƙwayar ƙwayar cuta a cikin binciken bincike na asali azaman wakili ɗaya kuma tare da haɗin gwiwa tare da masu hana wuraren bincike, yana mai da shi babban fifiko a cikin rigakafi-oncology.
Binciken zai kimanta aminci da haƙuri na GRC 54276 a matsayin monotherapy, da kuma a hade tare da masu hana wuraren bincike a cikin marasa lafiya masu ci gaba da ciwace-ciwacen ciwace-ciwacen ƙwayoyi da kuma Hodgkin's lymphoma. Glenmark zai fara gwajin asibiti na Mataki na 1 a Indiya nan da Yuni 2022, kuma yana shirin shigar da IND a cikin Aikace-aikacen gwaji na Amurka da na Clinical a Turai don fara cikakken shirin nazarin asibiti na duniya.
"Ƙoƙarin Glenmark shine samar da sababbin hanyoyin magance jiyya a cikin ainihin wuraren warkewa. Mun yi farin ciki da cewa sabon littafin mu na farko daga sabuwar ƙungiyar 'Innovative Medicine Group' a cikin Glenmark ta sami izini daga mai kula da magunguna na Indiya don fara gwajin asibiti na Mataki na 1. Wannan yana ƙarfafa ƙarfin haɓakar Glenmark na ingantaccen bincike na asibiti kuma mataki ne na kusa da samar da cikakkun hanyoyin magance cutar kansa, "in ji Glenn Saldanha, Shugaban & Manajan Darakta, Glenmark Pharmaceuticals Limited.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Glenmark will initiate Phase 1 clinical trial in India by June 2022, and also plans to file an IND in the US and Clinical Trial Applications in Europe to kick-off a fully global clinical study program.
- GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology.
- Glenmark Pharmaceuticals Limited received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel small-molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
